Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
A Phase II Study of Rapamycin (Rapamune, Sirolimus) and Trastuzumab (Herceptin) for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  6/5/2009
Yale Comprehensive Cancer Center at Yale University School of Medicine
mi
from
New Haven, CT
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
A Phase II Study of Rapamycin (Rapamune, Sirolimus) and Trastuzumab (Herceptin) for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 6/5/2009
Yale Comprehensive Cancer Center at Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  6/5/2009
Yale University, Yale Cancer Center
mi
from
New Haven, CT
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 6/5/2009
Yale University, Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
A Dose-Escalating and Phase II Clinical Trial of the Histone Deacetylase (HDAC) Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA, ZolinzaTM) in Combination With Capecitabine (XelodaTM) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Status: Enrolling
Updated:  6/5/2009
Yale University School of Medicine
mi
from
New Haven, CT
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
A Dose-Escalating and Phase II Clinical Trial of the Histone Deacetylase (HDAC) Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA, ZolinzaTM) in Combination With Capecitabine (XelodaTM) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Status: Enrolling
Updated: 6/5/2009
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated:  8/24/2009
Dana-Farber Cancer Institute
mi
from
Boston, MA
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated: 8/24/2009
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated:  8/24/2009
Massachusetts General Hospital
mi
from
Boston, MA
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated: 8/24/2009
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated:  8/24/2009
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated: 8/24/2009
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated:  8/24/2009
New Hampshire Oncology-Hematology PA
mi
from
Hooksett, NH
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated: 8/24/2009
New Hampshire Oncology-Hematology PA
mi
from
Hooksett, NH
Click here to add this to my saved trials
A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer
A Phase I Vaccine Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  8/25/2009
Quantum Immunologics
mi
from
Mobile, AL
A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer
A Phase I Vaccine Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 8/25/2009
Quantum Immunologics
mi
from
Mobile, AL
Click here to add this to my saved trials
Multi-Media Imagery Program for Breast Cancer Patients (Phase II)
Multi-Media Imagery Program for Breast Cancer Patients (Phase II)
Status: Enrolling
Updated:  12/16/2009
Gilda's Club Seattle
mi
from
Seattle, WA
Multi-Media Imagery Program for Breast Cancer Patients (Phase II)
Multi-Media Imagery Program for Breast Cancer Patients (Phase II)
Status: Enrolling
Updated: 12/16/2009
Gilda's Club Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Molecular Imaging of Breast Cancer With Breast PET/CT
Molecular Imaging of Breast Cancer With Breast PET/CT
Status: Enrolling
Updated:  1/19/2010
UC David Medical Center
mi
from
Sacramento, CA
Molecular Imaging of Breast Cancer With Breast PET/CT
Molecular Imaging of Breast Cancer With Breast PET/CT
Status: Enrolling
Updated: 1/19/2010
UC David Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Regenerative Tissue Matrix for Breast Reconstruction
In Situ Elasticity of Alloderm® in Breast Reconstruction
Status: Enrolling
Updated:  1/29/2010
Henry Ford Hospital
mi
from
Detroit, MI
Regenerative Tissue Matrix for Breast Reconstruction
In Situ Elasticity of Alloderm® in Breast Reconstruction
Status: Enrolling
Updated: 1/29/2010
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.
The Effects of Exercise Training on Tumor Vascularity and Response to Neoadjuvant Therapy in Operable Breast Cancer: A Phase I-II Study
Status: Enrolling
Updated:  2/11/2010
Duke Univ Med Ctr
mi
from
Durham, NC
Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.
The Effects of Exercise Training on Tumor Vascularity and Response to Neoadjuvant Therapy in Operable Breast Cancer: A Phase I-II Study
Status: Enrolling
Updated: 2/11/2010
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy
The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy
Status: Enrolling
Updated:  2/17/2010
FMHHS Cancer Care Center
mi
from
New Albany, IN
The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy
The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy
Status: Enrolling
Updated: 2/17/2010
FMHHS Cancer Care Center
mi
from
New Albany, IN
Click here to add this to my saved trials
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Status: Enrolling
Updated:  4/8/2010
Bruno Cancer Center
mi
from
Birmingham, AL
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Status: Enrolling
Updated: 4/8/2010
Bruno Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Status: Enrolling
Updated:  4/8/2010
Comprehensive Cancer Center
mi
from
Palm Springs, CA
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Status: Enrolling
Updated: 4/8/2010
Comprehensive Cancer Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Status: Enrolling
Updated:  4/8/2010
Research Institute of Deaconess Clinic
mi
from
Evansville, IN
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Status: Enrolling
Updated: 4/8/2010
Research Institute of Deaconess Clinic
mi
from
Evansville, IN
Click here to add this to my saved trials
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Status: Enrolling
Updated:  4/8/2010
Cancer Care Center
mi
from
New Albany, IN
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Status: Enrolling
Updated: 4/8/2010
Cancer Care Center
mi
from
New Albany, IN
Click here to add this to my saved trials
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Status: Enrolling
Updated:  4/8/2010
Kansas City Cancer Centers
mi
from
Overland Park, KA
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Status: Enrolling
Updated: 4/8/2010
Kansas City Cancer Centers
mi
from
Overland Park, KA
Click here to add this to my saved trials
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Status: Enrolling
Updated:  4/8/2010
Signal Point Clinical Research Center
mi
from
Middleton, OH
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Status: Enrolling
Updated: 4/8/2010
Signal Point Clinical Research Center
mi
from
Middleton, OH
Click here to add this to my saved trials
Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer
Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer
Status: Enrolling
Updated:  6/1/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer
Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer
Status: Enrolling
Updated: 6/1/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Evaluating an Internet-based Intervention for Insomnia in Breast Cancer Survivors
Evaluating an Internet-based Intervention for Insomnia in Breast Cancer Survivors
Status: Enrolling
Updated:  6/10/2010
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Evaluating an Internet-based Intervention for Insomnia in Breast Cancer Survivors
Evaluating an Internet-based Intervention for Insomnia in Breast Cancer Survivors
Status: Enrolling
Updated: 6/10/2010
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity
Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab
Status: Enrolling
Updated:  7/29/2010
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity
Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab
Status: Enrolling
Updated: 7/29/2010
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Evaluation of Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer
Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer
Status: Enrolling
Updated:  8/27/2010
Breast Care Specialist, PC
mi
from
Allentown, PA
Clinical Evaluation of Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer
Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer
Status: Enrolling
Updated: 8/27/2010
Breast Care Specialist, PC
mi
from
Allentown, PA
Click here to add this to my saved trials
Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors
Cancer Survivors Online Self-Management Workshop
Status: Enrolling
Updated:  9/8/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors
Cancer Survivors Online Self-Management Workshop
Status: Enrolling
Updated: 9/8/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Multipeptide Vaccine for Advanced Breast Cancer
A Study of hTERT/Survivin Multi-peptide Vaccine With Daclizumab and Prevnar for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  9/23/2010
University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Multipeptide Vaccine for Advanced Breast Cancer
A Study of hTERT/Survivin Multi-peptide Vaccine With Daclizumab and Prevnar for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 9/23/2010
University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study Of Ispinesib In Subjects With Breast Cancer
Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/1/2010
GSK Investigational Site
mi
from
Jacksonville, FL
Study Of Ispinesib In Subjects With Breast Cancer
Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/1/2010
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study Of Ispinesib In Subjects With Breast Cancer
Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/1/2010
GSK Investigational Site
mi
from
Indianapolis, IN
Study Of Ispinesib In Subjects With Breast Cancer
Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/1/2010
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study Of Ispinesib In Subjects With Breast Cancer
Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/1/2010
GSK Investigational Site
mi
from
Chapel Hill, NC
Study Of Ispinesib In Subjects With Breast Cancer
Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/1/2010
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study Of Ispinesib In Subjects With Breast Cancer
Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/1/2010
GSK Investigational Site
mi
from
Pittsburgh, PA
Study Of Ispinesib In Subjects With Breast Cancer
Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/1/2010
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study Of Ispinesib In Subjects With Breast Cancer
Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/1/2010
GSK Investigational Site
mi
from
Bruxelles,
Study Of Ispinesib In Subjects With Breast Cancer
Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/1/2010
GSK Investigational Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors: The Role of Aromatase Inhibitors
Status: Enrolling
Updated:  1/6/2011
Michigan Center for Oral Health Research
mi
from
Ann Arbor, MI
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors: The Role of Aromatase Inhibitors
Status: Enrolling
Updated: 1/6/2011
Michigan Center for Oral Health Research
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Breast Cancer Prevention Education
Disseminating Breast Cancer Prevention to African American Women
Status: Enrolling
Updated:  2/17/2011
University of Pennsylvania Center for Community Based Research and Health Disparities
mi
from
Philadelphia, PA
Breast Cancer Prevention Education
Disseminating Breast Cancer Prevention to African American Women
Status: Enrolling
Updated: 2/17/2011
University of Pennsylvania Center for Community Based Research and Health Disparities
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study Comparing the PET Scan and MRI in Identifying Breast Malignancies in Women With Breast Abnormalities
Comparative Study of the Diagnostic Accuracy of Scintimammography (Fluorine 18-FDG PET Scintigraphic Imaging) and Magnetic Resonance Imaging in Identifying Malignant Breast Lesions, In Subjects With Breast Abnormalities
Status: Enrolling
Updated:  4/26/2011
Central New York PET Center
mi
from
Liverpool, NY
Study Comparing the PET Scan and MRI in Identifying Breast Malignancies in Women With Breast Abnormalities
Comparative Study of the Diagnostic Accuracy of Scintimammography (Fluorine 18-FDG PET Scintigraphic Imaging) and Magnetic Resonance Imaging in Identifying Malignant Breast Lesions, In Subjects With Breast Abnormalities
Status: Enrolling
Updated: 4/26/2011
Central New York PET Center
mi
from
Liverpool, NY
Click here to add this to my saved trials
Study Comparing the PET Scan and MRI in Identifying Breast Malignancies in Women With Breast Abnormalities
Comparative Study of the Diagnostic Accuracy of Scintimammography (Fluorine 18-FDG PET Scintigraphic Imaging) and Magnetic Resonance Imaging in Identifying Malignant Breast Lesions, In Subjects With Breast Abnormalities
Status: Enrolling
Updated:  4/26/2011
Institute For Human Performance
mi
from
Syracuse, NY
Study Comparing the PET Scan and MRI in Identifying Breast Malignancies in Women With Breast Abnormalities
Comparative Study of the Diagnostic Accuracy of Scintimammography (Fluorine 18-FDG PET Scintigraphic Imaging) and Magnetic Resonance Imaging in Identifying Malignant Breast Lesions, In Subjects With Breast Abnormalities
Status: Enrolling
Updated: 4/26/2011
Institute For Human Performance
mi
from
Syracuse, NY
Click here to add this to my saved trials
Study Comparing the PET Scan and MRI in Identifying Breast Malignancies in Women With Breast Abnormalities
Comparative Study of the Diagnostic Accuracy of Scintimammography (Fluorine 18-FDG PET Scintigraphic Imaging) and Magnetic Resonance Imaging in Identifying Malignant Breast Lesions, In Subjects With Breast Abnormalities
Status: Enrolling
Updated:  4/26/2011
University Radiology Associates
mi
from
Syracuse, NY
Study Comparing the PET Scan and MRI in Identifying Breast Malignancies in Women With Breast Abnormalities
Comparative Study of the Diagnostic Accuracy of Scintimammography (Fluorine 18-FDG PET Scintigraphic Imaging) and Magnetic Resonance Imaging in Identifying Malignant Breast Lesions, In Subjects With Breast Abnormalities
Status: Enrolling
Updated: 4/26/2011
University Radiology Associates
mi
from
Syracuse, NY
Click here to add this to my saved trials
Partial Breast Irradiation in a Low-risk Population Screened With MRI
Image Guided Partial Breast Irradiation (PBL) In A Low-Risk Population Screened With Magnetic Resonance Imaging (MRI)
Status: Enrolling
Updated:  5/23/2011
University of Chicago
mi
from
Chicago, IL
Partial Breast Irradiation in a Low-risk Population Screened With MRI
Image Guided Partial Breast Irradiation (PBL) In A Low-Risk Population Screened With Magnetic Resonance Imaging (MRI)
Status: Enrolling
Updated: 5/23/2011
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Front Range Cancer Specialists
mi
from
Fort Collins, CO
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Front Range Cancer Specialists
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Front Range Cancer Specialists
mi
from
Loveland, CO
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Front Range Cancer Specialists
mi
from
Loveland, CO
Click here to add this to my saved trials
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
U T M D Anderson Cancer Center
mi
from
Houston, TX
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
U T M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer
Role of PEM Flex Solo II PET Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer
Status: Enrolling
Updated:  6/14/2011
University of Chicago Medical Center
mi
from
Chicago, IL
Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer
Role of PEM Flex Solo II PET Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer
Status: Enrolling
Updated: 6/14/2011
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue
A Phase II, Pilot, Randomized, Double-blind Study Comparing the Effectiveness Organic Germanium to Placebo in Decreasing the Severity of Fatigue in Patients Undergoing Radiation Therapy for Prostae and Bbreast Cancers
Status: Enrolling
Updated:  6/21/2011
Arizona Oncology Services
mi
from
Phoenix, AZ
Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue
A Phase II, Pilot, Randomized, Double-blind Study Comparing the Effectiveness Organic Germanium to Placebo in Decreasing the Severity of Fatigue in Patients Undergoing Radiation Therapy for Prostae and Bbreast Cancers
Status: Enrolling
Updated: 6/21/2011
Arizona Oncology Services
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer
A Phase II Study of NK012 in Locally Advanced Non-Resectable and Metastatic Breast Cancer Patients With Triple Negative Phenotype
Status: Enrolling
Updated:  6/24/2011
Sarah Cannon Research Institute
mi
from
Nashville, TN
A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer
A Phase II Study of NK012 in Locally Advanced Non-Resectable and Metastatic Breast Cancer Patients With Triple Negative Phenotype
Status: Enrolling
Updated: 6/24/2011
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
To Evaluate the Characteristics of a Breast Cancer
Pilot Study to Characterize the HRHV Axis in the Microenvironment of Breast Cancers
Status: Enrolling
Updated:  6/28/2011
Duke Univ Med Ctr
mi
from
Durham, NC
To Evaluate the Characteristics of a Breast Cancer
Pilot Study to Characterize the HRHV Axis in the Microenvironment of Breast Cancers
Status: Enrolling
Updated: 6/28/2011
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Fast Spectral Imaging Device for Tumor Margin Mapping
Fast Spectral Imaging Device for Tumor Margin Mapping
Status: Enrolling
Updated:  6/28/2011
Duke Univ Med Ctr
mi
from
Durham, NC
Fast Spectral Imaging Device for Tumor Margin Mapping
Fast Spectral Imaging Device for Tumor Margin Mapping
Status: Enrolling
Updated: 6/28/2011
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Bioelectrical Impedance for Self-monitoring of Lymphedema
Bioelectrical Impedance for Self-monitoring of Breast Cancer Related Lymphedema
Status: Enrolling
Updated:  6/28/2011
Vanderbilt Univeristy School Of Nursing
mi
from
Nashville, TN
Bioelectrical Impedance for Self-monitoring of Lymphedema
Bioelectrical Impedance for Self-monitoring of Breast Cancer Related Lymphedema
Status: Enrolling
Updated: 6/28/2011
Vanderbilt Univeristy School Of Nursing
mi
from
Nashville, TN
Click here to add this to my saved trials
Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients
Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients
Status: Enrolling
Updated:  7/8/2011
SUNY Upstate Medical University
mi
from
Syracuse, NY
Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients
Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients
Status: Enrolling
Updated: 7/8/2011
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Novel Prosocial Online Support Group for Distressed Breast Cancer Survivors
A Novel Prosocial Online Support Group for Distressed Breast Cancer Survivors
Status: Enrolling
Updated:  7/14/2011
Temple University
mi
from
Philadelphia, PA
A Novel Prosocial Online Support Group for Distressed Breast Cancer Survivors
A Novel Prosocial Online Support Group for Distressed Breast Cancer Survivors
Status: Enrolling
Updated: 7/14/2011
Temple University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Community Volunteers Promoting Physical Activity Among Cancer Survivors
Community Volunteers Promoting Physical Activity Among Cancer Survivors
Status: Enrolling
Updated:  7/21/2011
Centers for Behavioral and Preventive Medicine, The Miriam Hospital, One Hoppin Street, Suite 314
mi
from
Providence, RI
Community Volunteers Promoting Physical Activity Among Cancer Survivors
Community Volunteers Promoting Physical Activity Among Cancer Survivors
Status: Enrolling
Updated: 7/21/2011
Centers for Behavioral and Preventive Medicine, The Miriam Hospital, One Hoppin Street, Suite 314
mi
from
Providence, RI
Click here to add this to my saved trials
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies
Status: Enrolling
Updated:  9/2/2011
St Luke's - Roosevelt Hospital Center
mi
from
New York, NY
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies
Status: Enrolling
Updated: 9/2/2011
St Luke's - Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials